top of page

 

LIST (WITH SUMMARIES) OF PAGES WITH

ADDITIONAL SCIENTIFIC INFORMATION

TO HELP EXPLAIN OUR APPROACH

​

 

​

 

​

​

This page contains a list, with brief overviews, of topics that are addressed in more detail on the pages that follow. If you click on any red header, below, it will take you to a page with more info on that topic.

 

1. BRIEF INTRODUCTION TO MUCOSAL MEMBRANES, AND MUCOSAL PATHOGENS

 

          Mucous (or mucosal) membranes are very different from dry skin, aka “epidermis”. Epidermal cells actually are empty pseudo‑cells, created not by cell division, but by special precursor cells that expand rapidly, and then “pinch off” the expanded portion. That makes them ideal for absorbing and entrapping infective microbes, to prevent them from reproducing. By contrast, mucosal membranes are covered by complete and functional “epithelial” cells. As a result, they are major and constant targets and goals, for pathogenic microbes. “Mucosal pathogens” are – by far – the largest and most important class of pathogens; there are thousands of different types, compared to only a small number of “blood-borne” diseases transmitted by insect bites.

 

2. MALT PATCHES, AND HOW “M CELLS” SAMPLE AND PULL IN APPARENT PATHOGENS

 

         MALT (“mucosal associated lymphoid tissue”) patches are specialized lymph nodes, mounted on the outer exposed surfaces of mucous membranes. They are a crucial “first line of defense” against pathogens that try to infect mucous membrane cells.

         M cells are “sampling cells” on the surfaces of MALT patches. If they detect a particle carrying a “pathogen pattern”, they will grab it and pull it in, via a process called either "endocytosis" (a broader term) or "phagocytosis" (limited to particles, and excluding droplets); and, to protect the cell, the particle will be enclosed in a small membrane bubble, called an "endosome" or "phagosome".  Rather than processing it, an M cell will push that type of phagosome through the cell as rapidly as possible, and press it against the "basal" membrane of the M cell. When those two membranes merge, it will eject the particle (in naked/exposed form) into a “docking site”, which is a cup-shaped structure on the bottom of the M cell. A type of immune cell called an “immature” or “pre-committed” dendritic cell – will be waiting, in that docking site, for that type of “pathogen delivery” by the M cell.

         Therefore, “MALT-targeting” peptides are “pathogen pattern” peptides that can be attached to the surfaces of vaccine particles, so that they will “trick” the M cells into pulling them in, and passing them on to dendritic cells that are waiting for pathogen deliveries.

 

3. DENDRITIC CELLS ARE THE “GENIUS” CELLS WHICH CONTROL ANTIBODY-FORMING RESPONSES. THEREFORE, THEY ARE THE PERFECT TARGETS FOR “TARGETED TRANSPORT”  VACCINES CARRYING PATHOGEN SIGNALS WHICH MAKE THOSE VACCINE PARTICLES LOOK LIKE DANGEROUS PATHOGENS.

 

         Dendritic cells play the crucial role in determining: (i) which foreign particles are NOT really important and dangerous, and should be gobbled up and digested on the spot, without further ado; versus (ii) which foreign particles appear to be dangerous and important pathogens, which need to be taken to a lymph node (while being broken apart and semi‑digested along the way), so that T and B cells in a lymph node can make antibodies that will bind to those alien/invading particles.

          With the help of “chemo‑attractant” signals, newly‑formed dendritic cells find and settle into the “docking sites” on the undersides of M cells, to await a pathogen delivery that will cause them to transform from an “immature” dendritic cell, into an “antigen‑presenting” cell. Therefore, “MALT‑targeting peptides” ‑ attached to the surfaces of mucosal vaccine particles ‑ offer an ideal way to get those vaccine particles rapidly delivered to dendritic cells, and to get dendritic cells which receive those vaccine particles to do exactly what is needed, to launch an antibody‑forming response to any antigens which are present (in large copy numbers) on the surfaces of those vaccine particles.

 

4. WHEN AN “IMMATURE” DENDRITIC CELL ENCOUNTERS A PATHOGEN THAT MERITS AN ANTIBODY-FORMING RESPONSE, IT MOVES MULTIPLE CCR7 RECEPTOR PROTEINS FROM INSIDE THE CELL, TO THE OUTER SURFACE. THE CCR7 RECEPTORS CAN THEN BE CONTACTED BY A CHEMO-ATTRACTANT CALLED CCL19, WHICH GUIDES ACTIVATED DENDRITIC CELL TO “GERMINAL CENTERS” INSIDE LYMPH NODES.

 

          When dendritic cells are first formed, they are actively recruited, by a chemo-attractant cytokine released by M cells, to travel to and settle into “docking sites” on the “basal” sides of the M cells. Large numbers of dendritic cells go to those docking sites, to wait for “pathogen deliveries” by and from those M cells. They can remain in those docking sites for as long as necessary – i.e., until something “activates” them – because their CCR7 receptor proteins remain inside those “immature” cells, and cannot be contacted by any signaling molecules.

          That changes, dramatically, when an immature dendritic cell receives and analyzes a particle, and determines that it appears to be sufficiently dangerous and important to merit an antibody-forming response.

          When that happens, the cell will “translocate” its multiple CCR7 receptor proteins from inside the cell, to locations distributed around the outer surface of the cell. After they reach the surface, those CCR7 receptors will be triggered by a chemo-attractant molecule called CCL19.

          CCL19 is constantly being secreted and released by T cells inside the germinal centers of lymph nodes, and it provides the signals that enable activated dendritic cells to travel toward a lymph node. An activated dendritic cell will always travel in the direction of the highest concentration of CCL19 (that process is often called “climbing the gradient”).

          When it finally reaches a “germinal center” inside a lymph node, a dendritic cell will present semi-digested “chunks” of protein (from the surfaces of the foreign particle) to T and B cells. The T and B cells will then begin working together, to create antibodies that will bind to those foreign protein sequences. The dendritic cell will leave the lymph node, once its task is finished, and in some cases it might convert back into “immature” status again.

 

 

5. THE “TRANSLOCATION” OF CCR7 RECEPTORS FROM INSIDE AN IMMATURE DENDRITIC CELL, TO THE OUTSIDE OF THAT CELL (WHEN IT MATURES/ACTIVATES/TRANSFORMS INTO AN “ANTIGEN-PRESENTING CELL”) OFFERS A DIRECT WAY TO IDENTIFY “MALT-TARGETING” PEPTIDE SEQUENCES (aka HYPER-PATHOGEN PEPTIDES), BY USING A NEW “SCREENING TEST” ON CANDIDATES FROM A “PHAGE DISPLAY LIBRARY”.

 

          After the physiologist employed by Precision-Guided Vaccines LLC learned about (and recognized the importance of) how CCR7 receptors are “translocated” when a dendritic cell becomes activated, he figured out how to create and use a new type of “screening test”, on candidate particles from a “phage display library” (as summarized in the next topic, directly below). That new type of screening test uses the CCL19 chemo-attractant to isolate only those dendritic cells that had become “activated”, by contact with phage particles which happened to be carrying foreign peptide sequences which made those “winning” phage particles appear to be infective, and dangerous.

          The steps and the reagents that were used, in that new type of screening test, are described HERE. As a super-condensed summary, mixtures of phage-exposed mucosal cells, from mice, were loaded into the top chambers of vertical tubes, sitting in wells that contained the CCL19 chemo-attractant. That created a dual-chamber separating device, with a filter having 5-micron pores separating the mucosal cells (in the top chamber) from the CCL19 chemo-attractant (in the bottom chamber). The liquid level in the wells was high enough to enable the CCL19 to begin diffusing upward, through the filter, and begin contacting the mucosal cells, as soon as the tube-with-filter device (with phage-exposed mucosal cells, sitting on top of the filter) was lowered into the well.

          The ONLY cells that were both MOTIVATED . . . and ABLE . . . to squeeze through those 5-micron pores, to get to the bottom chamber (i.e., to reach the higher concentration of CCL19 below that filter), were dendritic cells which had become activated, and which had moved their CCR7 receptors to their outer surfaces.

          After 2 hours, cells that had reached the bottom chamber were collected, and then broken apart by a detergent that breaks up cell membranes, but does not affect the proteins that cover the phages. Whatever the cells released, when broken apart, was “plated” at low density, across agar plates with fresh host bacteria. Within 2 days, a small number of clonal phage colonies began to appear on the plates. Those clonal isolates were extracted, replicated in new host bacteria, and analyzed, to find out what amino acid sequences they were carrying in their foreign inserts. Those amino acid sequences were identified as “HYPER-pathogen peptides” that were able to trigger, and then drive, all the way to completion, not just one, but an entire sequence of responses, by not just one but two different types of immune cells, which work together and cooperate beautifully, in the surface-mounted lymph nodes called MALT patches.

 

6. PHAGES, “PHAGE LIBRARIES”, AND “SCREENING TESTS” THAT CAN BE USED TO ISOLATE THOSE FEW PHAGES, FROM AMONG MILLIONS OF CANDIDATES, WHICH CAN TRIGGER SPECIAL TYPES OF REACTIONS.

 

         A summary page which introduces phages, phage libraries, and screening tests, is provided HERE. As a very brief intro:

         “Phages” (originally called “bacteriophages”) are the smallest viruses ever discovered. Each type can infect only a small set of bacteria, and none can infect plants or animals, so they are treated as harmless and non‑pathogenic.

          Phage “libraries” (aka phage display libraries) contain billions of different phage particles. In the most widely-used type of library, each particle carries a single gene which has been engineered to carry a completely randomized (via chemical synthesis) sequence of 36 bases (12 codons, with 3 bases in each codon), which will encode a corresponding random 12-amino-acid peptide sequence. That “foreign insert” peptide sequence will be attached to the outer tips of all five copies of a long tentacle-like protein that the phages use to hunt for, and grab hold of, new bacterial cells which they can infect (this can be compared to gluing cheap rhinestones to all five fingernails, on a hand, with a few valuable gems hidden among the billions of rhinestones). Good phage libraries took decades to develop, but now, a top‑quality library with literally a trillion different “candidate” particles (all in a single tube; they are THAT small) can be purchased for less than $1000.

          “Screening tests” are clever ways, thought up by scientists, to subject several million phage particles (in each small batch that is tested in a specific “run”) to a fair competition, usually involving something like, “Uptake and processing, by a specific and unusual type of cell”. A well-designed screening test can enable scientists to isolate and then analyze those few phages which happen to be carrying an inserted/foreign peptide sequence which causes those cells to perform that activity (i.e., a screening test is designed to identify, and isolate, the rare valuable gems that are scattered among millions and millions of useless rhinestones). Rather than trying to predict, design, or control which protein sequences will be able to perform “the XYZ trick”, it is often easier to design a way to let millions of phages give it a try, and compete against each other, and figure out some way to isolate those phages which were able to do that particular trick. Later, after number of “first round winners” have been identified, a way to perform a "second round competition" can be thought up, to figure out which ones, among the "first round winners", can perform the desired trick most potently, effectively, rapidly, or whatever. And, after a "winner" has been identified, various ways can be used to create and test controlled and/or random mutants having 1 or 2 altered amino acids, to see if any of those might be even more potent and effective than a "starting point" (or "referent") winner, at performing the desired task. 

​​

That completes a summary/overview of various facts and factors that had to be recognized and assembled, to create a way to identify "MALT-targeting" peptide sequences (also called "HYPER-pathogen peptides") which can be attached to the ​surfaces of mucosal vaccine particles, to cause those vaccine particles to: (i) be taken in, transported, and ejected into a docking site, rapidly, by M cells on the surfaces of MALT patch lymph nodes; and, (ii) be able to trigger the maturation (aka activation, or transformation) of "immature" dendritic cells, into "mobile antigen-presenting cells". The next pages contain more information on each of the topics listed above.

​

bottom of page